Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · July 26, 2017

Durable Molecular Remissions in CLL Treated With CD19-Specific CAR T Cells After Failure of Ibrutinib

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
J. Clin. Oncol 2017 Jul 17;[EPub Ahead of Print], CJ Turtle, KA Hay, LA Hanafi, D Li, S Cherian, X Chen, B Wood, A Lozanski, JC Byrd, S Heimfeld, SR Riddell, DG Maloney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading